Drug Search Results
More Filters [+]

Becatecarin

Alternative Names: becatecarin
Latest Update: 2014-05-23
Latest Update Note: Clinical Trial Update

Product Description

Becatecarin (rebeccamaycin analogue-RA) is an anti-tumor antibiotic with inhibitory activity against both topoisomerase II and I as well as DNA intercalating properties. (Sourced from: https://ascopubs.org/doi/10.1200/jco.2008.26.15_suppl.19060)

Mechanisms of Action: TOP2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Helsinn Healthcare
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Becatecarin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Renal Cell Carcinoma|Cholangiocarcinoma|Kidney Cancer|Colorectal Cancer|Small Cell Lung Cancer|Liver Cancer|Gallbladder Cancer|Retinoblastoma|Brain Stem Cancer|Neuroblastoma|Bile Duct Cancer|Non-Small-Cell Lung Cancer|Sarcoma|Ovarian Cancer|Primary Central Nervous System Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCI-2012-02587

P2

Terminated

Small Cell Lung Cancer

2008-04-01

CDR0000066852

P2

Completed

Neuroblastoma

2006-09-01

NCI-2012-01851

P2

Completed

Sarcoma|Retinoblastoma|Primary Central Nervous System Lymphoma|Brain Stem Cancer|Neuroblastoma

2006-06-01

CWRU2299

P2

Terminated

Gallbladder Cancer|Liver Cancer|Bile Duct Cancer|Cholangiocarcinoma

2005-04-01

Recent News Events

Date

Type

Title